NASDAQ:RNXT RenovoRx (RNXT) Stock Price, News & Analysis → top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL) (From Traders Agency) (Ad) Free RNXT Stock Alerts $1.24 +0.03 (+2.23%) (As of 03:01 PM ET) Add Compare Share Share Today's Range$1.22▼$1.2550-Day Range$1.14▼$1.7852-Week Range$0.53▼$3.29Volume2,961 shsAverage Volume58,066 shsMarket Capitalization$20.92 millionP/E RatioN/ADividend YieldN/APrice Target$8.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Get RenovoRx alerts: Email Address RenovoRx MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.67 Rating ScoreUpside/Downside580.1% Upside$8.50 Price TargetShort InterestHealthy0.45% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.00Based on 4 Articles This WeekInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.67 out of 5 starsMedical Sector848th out of 907 stocksPharmaceutical Preparations Industry398th out of 422 stocks 3.3 Analyst's Opinion Consensus RatingRenovoRx has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageRenovoRx has only been the subject of 1 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.45% of the float of RenovoRx has been sold short.Short Interest Ratio / Days to CoverRenovoRx has a short interest ratio ("days to cover") of 1.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in RenovoRx has recently increased by 274.29%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldRenovoRx does not currently pay a dividend.Dividend GrowthRenovoRx does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for RNXT. Previous Next 0.0 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 4 news articles for RenovoRx this week, compared to 1 article on an average week. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, RenovoRx insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 9.00% of the stock of RenovoRx is held by insiders.Percentage Held by InstitutionsOnly 3.10% of the stock of RenovoRx is held by institutions. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of RenovoRx is -1.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of RenovoRx is -1.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Stansberry ResearchWorld’s biggest multibillionaire investor is buying THIS by the ton [picture]Don't Buy Bullion or Mining Stocks. Do THIS Instead As gold continues to break all-time highs, many folks will run out and buy bullion or mining stocks. That's not the best way to ride this gold bull market higher. Note, this showed a 995% gain the last time we shared this same investment idea.Click here to find out what to do. About RenovoRx Stock (NASDAQ:RNXT)RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of solid tumors. Its lead product candidate is RenovoGem, a drug and device combination consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. The company has a research collaboration with Imugene Limited to deliver oncolytic virus therapy for the treatment of difficult-to-access tumors. The company was founded in 2009 and is headquartered in Los Altos, California.Read More RNXT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart RNXT Stock News HeadlinesApril 23, 2024 | americanbankingnews.comRenovoRx (NASDAQ:RNXT) Trading 5.1% Higher April 20, 2024 | investing.comRenovoRx meets Nasdaq stockholders equity requirementApril 25, 2024 | Stansberry Research (Ad)World’s biggest multibillionaire investor is buying THIS by the ton [picture]Don't Buy Bullion or Mining Stocks. Do THIS Instead As gold continues to break all-time highs, many folks will run out and buy bullion or mining stocks. That's not the best way to ride this gold bull market higher. Note, this showed a 995% gain the last time we shared this same investment idea.April 18, 2024 | fr.investing.comRenovoRx répond aux exigences du Nasdaq en matière de capitaux propresApril 18, 2024 | businesswire.comRenovoRx Regains Compliance with Nasdaq Stockholders' Equity RequirementApril 16, 2024 | businesswire.comRenovoRx Highlights Recent Presentation of Clinical Data Abstract at the 2024 Society of Interventional Radiology Annual Scientific MeetingApril 15, 2024 | finance.yahoo.comRenovoRx Closes $11.1 Million Private Placement, Providing Cash Runway into 2026April 15, 2024 | businesswire.comRenovoRx Closes $11.1 Million Private Placement, Providing Cash Runway into 2026April 25, 2024 | Stansberry Research (Ad)World’s biggest multibillionaire investor is buying THIS by the ton [picture]Don't Buy Bullion or Mining Stocks. Do THIS Instead As gold continues to break all-time highs, many folks will run out and buy bullion or mining stocks. That's not the best way to ride this gold bull market higher. Note, this showed a 995% gain the last time we shared this same investment idea.April 8, 2024 | investorplace.comRNXT Stock Earnings: RenovoRx Meets EPS for Q4 2023April 8, 2024 | investorplace.comRNXT Stock Earnings: RenovoRx Meets EPS for Q4 2023April 8, 2024 | businesswire.comRenovoRx Announces $11.1 Million at Market Private PlacementApril 5, 2024 | businesswire.comRenovoRx to Present at the Canaccord Genuity Horizons in Oncology Virtual Conference on April 15, 2024March 12, 2024 | finance.yahoo.comRenovoRx to Present at the 36th Annual ROTH Conference on March 19, 2024March 10, 2024 | investing.comRenovoRx announces key leadership promotionsMarch 8, 2024 | fr.investing.comRenovoRx annonce des promotions à des postes clésMarch 8, 2024 | finance.yahoo.comRenovoRx Highlights Key Leadership PromotionsFebruary 6, 2024 | fr.investing.comRenovoRx obtient un financement pour un essai de phase III sur le cancerJanuary 29, 2024 | msn.comRenovoRx closes $6.1M private placementJanuary 29, 2024 | finance.yahoo.comRenovoRx Closes $6.1 Million Private PlacementDecember 21, 2023 | finance.yahoo.comRenovoRx Engages Oklahoma University (OU) Health as First Clinical Site in Preparation for the Pivotal Phase III CouGar Clinical Trial in Bile Duct CancerDecember 19, 2023 | finance.yahoo.comRenovoRx Announces Clinical Data Abstract at the 2024 Society of Interventional Radiology Annual Scientific MeetingDecember 13, 2023 | finance.yahoo.comRenovoRx Files New International Patent for Novel Targeted Combination Drug-Delivery Oncology Therapy PlatformDecember 9, 2023 | morningstar.comRenovoRx Inc RNXTNovember 16, 2023 | msn.comMaxim Group Downgrades RenovoRx (RNXT)November 16, 2023 | finance.yahoo.comRenovoRx Expands Scientific Advisory Board with Appointment of Michel Ducreux, M.D., Ph.D.November 14, 2023 | msn.comRenovoRx GAAP EPS of -$0.13See More Headlines Receive RNXT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for RenovoRx and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings4/01/2024Today4/25/2024Next Earnings (Estimated)5/20/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:RNXT CUSIPN/A CIK1574094 Webwww.renovorx.com Phone650-284-4433Fax650-397-4433Employees8Year FoundedN/APrice Target and Rating Average Stock Price Target$8.50 High Stock Price Target$13.00 Low Stock Price Target$4.00 Potential Upside/Downside+580.1%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($1.01) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-10,230,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-2,860.14% Return on Assets-261.49% Debt Debt-to-Equity RatioN/A Current Ratio1.16 Quick Ratio1.16 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.28) per share Price / Book-4.46Miscellaneous Outstanding Shares16,870,000Free Float15,348,000Market Cap$21.09 million OptionableNot Optionable Beta1.04 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesDr. Ramtin Agah M.D. (Age 57)Founder, Chairman of Board & Chief Medical Officer Comp: $332.89kMr. Shaun R. Bagai (Age 47)CEO & Director Comp: $589.38kMr. Ronald B. Kocak CPA (Age 67)CGMA, VP, Controller & Principal Accounting Officer Ms. Leesa Gentry (Age 54)Chief Clinical Officer Key CompetitorsVincerx PharmaNASDAQ:VINCAddex TherapeuticsNASDAQ:ADXNAptorum GroupNASDAQ:APMBioVieNASDAQ:BIVIOnconova TherapeuticsNASDAQ:ONTXView All CompetitorsInsiders & InstitutionsNixon Peabody Trust Co.Bought 97,165 shares on 2/9/2024Ownership: 0.909%Angela NelmsBought 1,100 shares on 10/3/2023Total: $1,155.00 ($1.05/share)View All Insider TransactionsView All Institutional Transactions RNXT Stock Analysis - Frequently Asked Questions Should I buy or sell RenovoRx stock right now? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for RenovoRx in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" RNXT shares. View RNXT analyst ratings or view top-rated stocks. What is RenovoRx's stock price target for 2024? 3 brokerages have issued 1 year target prices for RenovoRx's shares. Their RNXT share price targets range from $4.00 to $13.00. On average, they predict the company's share price to reach $8.50 in the next year. This suggests a possible upside of 580.1% from the stock's current price. View analysts price targets for RNXT or view top-rated stocks among Wall Street analysts. How have RNXT shares performed in 2024? RenovoRx's stock was trading at $2.29 at the start of the year. Since then, RNXT stock has decreased by 45.4% and is now trading at $1.2499. View the best growth stocks for 2024 here. Are investors shorting RenovoRx? RenovoRx saw a increase in short interest during the month of April. As of April 15th, there was short interest totaling 65,500 shares, an increase of 274.3% from the March 31st total of 17,500 shares. Based on an average daily trading volume, of 47,900 shares, the days-to-cover ratio is presently 1.4 days. Currently, 0.5% of the company's stock are short sold. View RenovoRx's Short Interest. When is RenovoRx's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024. View our RNXT earnings forecast. How were RenovoRx's earnings last quarter? RenovoRx, Inc. (NASDAQ:RNXT) announced its quarterly earnings results on Monday, April, 1st. The company reported ($0.17) EPS for the quarter. When did RenovoRx IPO? RenovoRx (RNXT) raised $18 million in an IPO on Thursday, August 26th 2021. The company issued 1,800,000 shares at $9.00-$11.00 per share. Roth Capital Partners and Maxim Group LLC acted as the underwriters for the IPO. How do I buy shares of RenovoRx? Shares of RNXT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:RNXT) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarThe A.I. story nobody is telling you (Read ASAP)TradeSmithRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldHe Is Giving Away BitcoinCrypto Swap Profitstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyYour Money is Not SafeAmerican Alternative Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding RenovoRx, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
